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A B S T R A C T   
Background: Platelets release platelet-derived extracellular vesicles (PDEVs) upon activation – in a process that is 
regulated by generation of reactive oxygen species (ROS). Platelet NADPH oxidase-1 (Nox-1) contributes to ROS 
generation and thrombus formation downstream of the collagen receptor GPVI. 
Objectives: We aimed to investigate whether PDEVs contain Nox-1 and whether this is relevant for PDEV-induced 
platelet activation. 
Methods: PDEVs were isolated through serial centrifugation after platelet activation with thrombin receptor 
agonist TRAP-6 (activated PDEVs) or in the absence of agonist (resting PDEVs). The physical properties of PDEVs 
were analyzed through nanoparticle tracking analysis. Nox-1 levels, fibrinogen binding and P-selectin exposure 
were measured using flow cytometry, and protein levels quantified by immunoblot analysis. ROS were quantified 
using DCF fluorescence and electron paramagnetic resonance. 
Results: Nox-1 was found to be increased on the platelet outer membrane upon activation and was present in 
PDEVs. PDEVs induced platelet activation, while co-addition of GPVI agonist collagen-related peptide (CRP) did 
not potentiate this response. PDEVs were shown to be able to generate superoxide in a process at least partially 
mediated by Nox-1, while Nox-1 inhibition with ML171 (also known as 2-APT) did not influence PDEV pro-
duction. Finally, inhibition of Nox-1 abrogated PDEV-mediated platelet activation. 
Conclusions: PDEVs are able to generate superoxide, bind to and activate platelets in a process mediated by Nox- 
1. These data provide novel mechanisms by which Nox-1 potentiates platelet responses, thus proposing Nox-1 
inhibition as a feasible strategy to treat and prevent thrombotic diseases.   
1. Introduction 
Upon vascular injury, platelets adhere to the subendothelium to 
maintain vascular integrity during damage or inflammation (reviewed 
in Ref. [1]). However, excessive platelet activation leads to thrombus 
formation and the development of cardiovascular diseases, such as 
atherosclerosis and thrombosis [2]. Reactive oxygen species (ROS) are 
key mediators of platelet function and are produced by activated 
platelets [3]. Indeed, enzymes that generate ROS, such as the NADPH 
oxidases 1 (Nox-1) and 2 (Nox-2) can control platelet activation [4]. 
Nox-1 and 2 are enzymatic complexes responsible for superoxide gen-
eration that are expressed on the outer membrane of cardiovascular 
cells, such as platelets [5], vascular smooth muscular cells (VSMC) [6] 
and endothelial cells [7]. Initially, Nox-2 was shown to be relevant to 
collagen receptor (GPVI)-mediated responses and regulate thrombus 
formation in male mice [8]. This has been disputed by us [9,10] and 
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others [11,12] that showed that Nox-1 is the relevant isotype in 
GPVI-mediated responses, whilst Nox-2 is dispensable for thrombus 
formation. Such discrepant result across groups may be due to sex dis-
parities amongst studies, as the initial report of Delaney et al. used male 
Nox-1-deficient mice [8], whilst we have used female mice, noting that 
the Nox-1 gene is on the X chromosome [9]. 
Notably, ROS modulate the production of extracellular vesicles (EVs) 
in various cells [13]; for instance, inhibition of NADPH oxidases and 
nitric oxide synthase-2 (NOS-2) in neutrophils reduce EVs generation 
[14]. Activated platelets also release EVs (also known as microparticles), 
which are heterogeneous circular bodies between 40 and 1500 nm 
derived from the cell membrane (microvesicles) or produced through 
exocytosis of multi-vesicular bodies (exosomes) [15]. Platelet-derived 
extracellular vesicles (PDEVs) potentiate thrombus formation, coagula-
tion and inflammation [16–18]. Despite increasing evidence describing 
the relevance of PDEVs to chronic diseases such as diabetes [19] and 
acute coronary syndrome [20], there is limited literature exploring how 
PDEVs interact with platelets and modulate their functions. It is 
currently unclear how PDEVs interact with platelets, although it has 
been shown for other cells that EVs can fuse, adhere and internalize via a 
receptor-mediated mechanism [21]. In addition, it is not known whether 
ROS-generating enzymes affect the production of PDEVs or indeed if 
PDEVs themselves are able to generate ROS. 
Therefore, we aimed to investigate if PDEVs express Nox-1 and the 
relevance of this enzyme to PDEV-mediated platelet activation. Here we 
show that Nox-1 translocates to the membrane of activated platelets and 
is expressed by PDEVs. PDEVs generate superoxide in a Nox-1- 
dependent way. We demonstrate that these EVs bind to platelets and 
enhance fibrinogen binding, in a process mediated by Nox-1. The 
investigation of novel redox mechanisms by which PDEVs activate 
platelets can enhance development of alternative strategies to tackle 
thrombotic diseases. 
2. Materials and methods 
Detailed methods are described in Supplementary Material. 
2.1. Preparation of platelet-derived extracellular vesicles 
PDEVs were isolated through centrifugation, as previously described 
[16,22,23] with minor modifications. Washed platelets (WP) were 
unstimulated (resting PDEVs) or activated with TRAP-6 (activated 
PDEVs) for 1 h at 37 ◦C. Platelets were removed by two 10 min centri-
fugations at 1,200 g. To concentrate PDEVs, supernatants were centri-
fuged at 15,000×g for 30 min. Pellets were resuspended in modified 
Tyrode’s buffer (134 mM NaCl, 20 mM N-2-hydroxyethylpiper-
azine-N′-2-ethanesulfonic acid, 12 mM NaHCO3 5 mM glucose, 0.34 mM 
Na2HPO4, 9 mM KCl and 1 mM MgCl2, pH 7.3) and immediately used or 
frozen at -80 ◦C. PDEVs protein concentrations were determined using a 
microvolume spectrophotometer (Nanodrop). A vehicle solution of 
equiosmolar TRAP-6 submitted to the same steps used to generate 
PDEVs was used to control for potential agonist carry-over. 
2.2. Collection of mouse blood and preparation of WP and PDEV 
Nox-1− /− female mice [24] aged 11–14 weeks were purchased from 
Jackson Laboratory (Sacramento, CA, USA) and C57BL/6 used as 
wildtype controls, as recommended by the animal provider. Animals 
were given food and water ad libitum and kept under a 12 h light cycle at 
22–24 ◦C. The Animal Welfare and Ethics Research Boards of the Uni-
versities of Reading and Exeter and the British Home Office approved all 
in vivo procedures. Mice were culled by rising CO2 and blood was 
collected into a syringe containing 3.2% sodium citrate (1:9 v/v citrate: 
blood ratio). Whole blood was centrifuged at 203×g for 8 min and PRP 
collected. 1.25 μg/mL PGI2 was added and PRP centrifuged at 1028×g 
for 5 min and pellet resuspended in modified modified Tyrode’s buffer to 
obtain WP. This was activated with thrombin for 1 h and centrifuged at 
1100×g for 10 min and supernatant containing PDEVs collected. This 
step was repeated and PDEV-containing supernatant was centrifuged at 
22,000×g for 45 min. The supernatant was discarded, the PDEVs pellet 
resuspended in Tyrode’s-HEPES buffer and used immediately. 
Fig. 1. Nox-1 is recruited to the platelet 
surface upon activation and expressed by 
PDEVs. Washed platelets (WP, 4 × 107 
platelets/mL) were activated with CRP (A) 
or TRAP-6 (B) for 10 min, prior to addition 
of anti-Nox-1 antibody for 10 min and Alexa 
488-tagged secondary antibody for 20 min. 
A condition in which the primary anti-Nox-1 
antibody was substituted for an IgG control 
is shown. Events acquired using a flow cy-
tometer. (C) Platelet-derived extracellular 
vesicles (PDEVs) were generated from 
platelets activated with 30 μM TRAP-6. 
PDEVs or WP were lysed and immunoblots 
performed according to standard proced-
ures. Representative blots of Nox-1 and 
loading controls GAPDH or β-actin are 
shown. Data expressed as mean ± SEM and 
individual points. Data analyzed by paired 
Student t-test. *p < 0.05.   
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2.3. Measurement of reactive oxygen species 
Intracellular superoxide formation was measured by electron para-
magnetic resonance (EPR), as described previously [9]. Briefly, WP were 
resuspended in Tyrode’s-HEPES buffer containing 25 μM deferroxamine 
and 5 μM diethyldithiocarbamate. PDEVs were incubated with 200 μM 
cyclic hydroxylamine 1-hydroxy-. 3-methoxycarbonyl-2,2,5,5-tetrame-
thylpyrrolidine (CMH) for 90 min to detect superoxide. Inhibitors 
ML171 or VAS2870 (Nox-1, Nox-2 and Nox-4 inhibitor) were added 
when appropriate and measured using an e-scan (Noxygen, Germany). 
2.4. Flow cytometry 
To assess surface levels of Nox-1, WP were kept at resting or acti-
vated with CRP or TRAP-6 for 10 min, and Nox-1 detected by flow 
cytometry usingan anti-Nox-1 antibody (1:250 v/v, NBP1-31546, Bio- 
techne R&D Systems, UK) and Alexa-488-tagged secondary antibody 
(1:100 v/v). A primary IgG isotype was used to control for non-specific 
binding. 
To test whether PDEVs bind to platelets, PDEVs were isolated from 
resting or TRAP-6-activated CSFE-loaded (4 μM) WP. CSFE-loaded 
PDEVs (0–50 μg/mL) were added to WP and fluorescence measured 
using flow cytometery. 
WP were incubated for 20 min with ML171 or Vehicle (DMSO 0.1% 
v/v in Tyrode’s-HEPES buffer) and treated with PDEVs (0–50 μg/mL) or 
washed TRAP-6 vehicle. In some experiments, CRP was included. Then, 
platelets were incubated with FITC-conjugated anti-fibrinogen (1:50 v/ 
v, F011102-2, Agilent, UK), PE/Cy5-conjugated anti-human CD62P 
(1:50 v/v, 551142, BD Biosciences) or Cy5-conjugated Annexin V (1:50 
v/v, 559934, BD Biosciences) for 30 min. Events were acquired using a 
BD Accuri C6 plus flow cytometer (BD Biosciences, UK). 
2.5. Statistical analysis 
Statistical analyses were performed on GraphPad Prism 8.0 software. 
Bar graphs express individual values and mean ± SEM while sample size 
varied between 3 and 8 independent donors/mice. Student t-tests 
compared differences between two groups while either one-way or two- 
way ANOVA with Tukey as post-test were used if more than two groups 
were tested. Experiments using human blood were paired, while data 
from mice were unpaired. Outliers were determined and excluded by 
ROUT method. Differences were deemed significant when p < 0.05. 
3. Results 
3.1. Nox-1 is recruited to the platelet surface upon activation and 
expressed by PDEVs 
We first assessed whether Nox-1 can be recruited to the surface of 
activated platelets by flow cytometry. Surface Nox-1 levels were 
increased by 35% upon addition of 1 μg/mL CRP and by 84% when 3 μg/ 
mL CRP was used (Fig. 1A). Similarly, Nox-1 levels increased by ~70% 
upon activation with TRAP-6 at both concentrations tested (Fig. 1B). If 
surface localised Nox-1 levels increased upon activation, it is possible 
that this is a consequence of binding of PDEVs to platelets, therefore we 
assessed if Nox-1 is also expressed in PDEVs. Immunoblot analysis 
revealed Nox-1 is present in PDEVs (Fig. 1C). In our experimental con-
ditions, from 4 × 108 platelets we were able to isolate 3.19 × 108 PDEVs 
if platelets were left resting (no agonist) and 4.82 × 108 PDEVs if 
stimulated with 30 μM TRAP-6 for 1 h (Supplementary Fig. 1). Notably, 
Nox-1 inhibition did not decrease the number or size of PDEVs (Sup-
plementary Fig. 1). 
3.2. Nox-1 in PDEVs regulates superoxide generation 
The primary role of Nox-1 is to generate superoxide, thus using EPR 
we examined whether PDEVs produce superoxide. Inhibition of Nox-1 
with ML171 decreased superoxide production by approximately 40%, 
while incubation of VAS2870, an inhibitor of several Nox isoforms [25], 
exerted a decrease of similar magnitude (Fig. 2A and B). This suggests 
Nox-1 is key for superoxide generation by PDEVs. To confirm this 
observation PDEVs were isolated from Nox-1− /− mice and compared 
with wildtype controls. Similar to ML171-treated human PDEVs, 
Nox-1− /− PDEVs exhibited an approximately 42% decrease in super-
oxide production when compared to their wildtype counterparts (Fig. 2C 
and D). In addition, PDEVs expressed key signalling molecules upstream 
Fig. 2. PDEVs generate superoxide in 
a Nox-1-dependent way. Superoxide 
was detected using electron para-
magnetic resonance (EPR). (A) Repre-
sentative EPR traces of human PDEVs 
incubated with selective Nox inhibitor 
ML171 or nonspecific Nox inhibitor 
VAS2870. (B) Quantification of data in 
(A). (C) Representative EPR traces of 
PDEVs from Nox-1− /− or wildtype (WT) 
mice. (D) Quantification of data in (C). 
Data analyzed by paired one-way 
ANOVA followed by Tukey’s post-test 
in B and by paired Student t-test in D. 
*p < 0.05.   
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Fig. 3. PDEVs are able to bind and acti-
vate platelets. (A) PDEVs were generated 
from platelets loaded with intracellular dye 
CSFE (4 μM) that were activated with 30 μM 
TRAP-6 (activated PDEVs) or kept without 
agonist (resting PDEVs) for 1 h. Resting and 
activated PDEVs were always used at the 
same concentration to allow comparisons 
between one another. PDEVs were incubated 
with platelets at increasing concentrations 
and median fluorescence intensity (MFI) 
measured using a flow cytometer. (B and C) 
activated PDEVs, collagen-related peptide 
(CRP) or both were incubated for 20 min 
with fresh platelets and FITC-conjugated 
anti-fibrinogen (A) or Cy-5-conjugated 
Annexin V (B) added for 30 min. Events 
were acquired using a flow cytometer. Data 
express mean ± SEM and individual points. 
Data analyzed by paired two-way (A) or one- 
way (B and C) ANOVA and Tukey’s post-test. 
*p < 0.05; **p < 0.01. ***p < 0.001.   
Fig. 4. Nox-1 inhibition abrogates 
PDEV-induced platelet activation. 
PDEVs from resting or TRAP-6-activated 
platelets were incubated with 3 μM 
ML171 or vehicle for 10 min. PDEV were 
then added to washed platelets (WP 4 ×
107 platelets/mL) for 20 min. The final 
concentration of ML171 in the presence 
of WP was 0.3 μM. FITC-conjugated anti- 
fibrinogen and PE/Cy5-conjugated anti- 
human CD62P were added for 30 min. 
Events were acquired using a BD Accuri 
C6 plus flow cytometer. (A) Fibrinogen 
binding and (B) P-selectin exposure of 
platelets incubated with resting PDEVs. 
(C) Fibrinogen binding and (D) P-selec-
tin exposure of platelets incubated with 
activated PDEVs. Data express mean ±
SEM and n = 4 independent donors. 
Data analyzed by paired two-way 
ANOVA followed by Tukey’s post-test. 
*p < 0.05; **p < 0.01. ns = non- 
significant.   
R.S. Gaspar et al.                                                                                                                                                                                                                               
Free Radical Biology and Medicine 165 (2021) 395–400
399
and downstream of Nox-1, while activation of protein kinase C in PDEVs 
did not potentiate ROS generation (Supplementary Fig. 2). Together, 
these data suggest that PDEVs express a constitutively active Nox-1 
system and that Nox-1 inhibition or genetic deletion decreased super-
oxide generation in PDEVs. 
3.3. PDEVs are able to bind to and activate platelets 
PDEVs were generated from resting and TRAP-6-activated WP in the 
presence of a fluorescent intracellular dye, CSFE. CSFE-loaded PDEVs 
were incubated with platelets at increasing concentrations and fluores-
cence measured using flow cytometry. We report that PDEVs generated 
by TRAP6-dependent platelet activation bound more to WP than PDEVs 
generated from resting platelets (Fig. 3A, 57% fluorescence increase at 
50 μg/mL PDEVs, p = 0.0038), confirming that PDEVs from resting and 
activated platelets have different phenotypes [26]. 
After establishing that PDEVs are able to bind platelets, we investi-
gated their effect on platelet activation. WP were incubated with or 
without 50 μg/mL PDEVs and/or 0.5 μg/mL CRP after which binding of 
fibrinogen and Annexin V , a marker of phosphatidylserine exposure, 
was measured (Fig. 3B and C). Importantly, to control for agonist carry- 
over, ‘vehicle’ was a condition in which 30 μM TRAP-6 was submitted to 
the same steps to obtain PDEVs. Likewise, 0.5 μg/mL CRP used in our 
assays elicited only 30% of the maximal fibrinogen bindin response 
induced by 3 μg/mL CRP (data not shown). Incubation with PDEVs 
increased fibrinogen binding when compared to vehicle-treated WP 
(Figs. 3B and 438% increase, p = 0.041), but did not potentiate platelet 
activation or phosphatidylserine exposure induced by CRP. The lack of 
additive effects between PDEVs and CRP suggest that GPVI or signals 
downstream of this receptor could be involved in PDEV-induced platelet 
activation. 
3.4. Nox-1 mediates platelet activation induced by PDEVs 
Finally, we determined the relevance of Nox-1 to PDEV-mediated 
platelet activation. PDEVs generated from resting or TRAP-6-activated 
platelets were treated with 3 μM ML171, a selective Nox-1 inhibitor 
[27,28] and incubated with WP to measure platelet activation by flow 
cytometry (Fig. 4). The final concentration of ML171 in contact with 
platelets was 0.3 μM. Importantly, only concentrations higher than 0.75 
μM ML171 were able to consistently inhibit both fibrinogen binding and 
P-selectin exposure induced by CRP (Supplementary Fig. 3). PDEVs from 
activated platelets increased P-selectin exposure to a greater extent than 
PDEVs generated from resting platelets (Supplementary Fig. 4). In 
addition, ML171 reduced platelet activation induced by PDEVs gener-
ated from resting and TRAP-6-activated platelets (Fig. 4A – D). This 
inhibitory effect of ML171 was more prominent when activated PDEVs 
were used, leading to a 54% decrease in fibrinogen binding and over 
60% decrease in P-selectin exposure (Fig. 4C and D). Therefore, these 
data show that Nox-1 is key to PDEV-induced platelet activation. 
4. Discussion 
Data presented herein show that PDEVs bind to platelets in a process 
regulated by Nox-1, which is downstream of the collagen receptor GPVI. 
We report that Nox-1 is recruited to the platelet surface upon activation 
and that PDEVs express Nox-1. PDEVs also express key components 
necessary for Nox-1 activation, such as p47phox and generate super-
oxide in a Nox-1-dependent manner. Finally, PDEVs induced platelet 
activation; an effect blunted in the presence of the Nox-1 inhibitor 
ML171. 
Several mechanisms have been shown to govern the generation of 
extracellular vesicles (EVs) in eukaryotic cells, such as outward blebbing 
of the plasma membrane, generation of apoptotic bodies and release of 
exosomes from intracellular compartments. It is believed that upon 
activation platelets shed vesicles through outward blebbing, as do most 
other cells (reviewed in Ref. [21]). Resting platelets could generate 
PDEVs through other mechanisms, such as apoptosis, release of exo-
somes or through physiological blebbing of the outer plasma membrane. 
Other groups have shown that resting platelets are able to generate 
PDEVs [29]. Indeed, resting PDEVs are phenotypically and functionally 
different from those generated upon stimulation with TRAP-6 [26]. This 
notion is reinforced here, as depicted in Figs. 3A and 4 and Supple-
mentary Fig. 4. It is also possible that the process of platelet washing and 
the buffer in which platelets were resuspended could influence the 
release of PDEVs. 
Nox-1 mediates platelet activation and ROS generation downstream 
of GPVI [9]. Here we show that Nox-1 is recruited to the outer surface of 
stimulated platelets and transferred to PDEVs. Similarly, Maitra et al. 
[30] showed lipopolysaccharide treatment increased Nox-1 protein 
levels in macrophages. In contrast, anucleate platelets have limited ca-
pacity to synthesize proteins, although extranuclear mechanisms may 
regulate minimal protein synthesis through translation of 
megakaryocyte-derived mRNA [31]. Since Nox-1 is a transmembrane 
protein, it is likely secreted on PDEVs that can bind to adjacent platelets, 
thus increasing their membrane-bound Nox-1 levels. 
EVs from ischaemic muscle generate ROS and express components of 
the NADPH oxidase complex, such as p47phox and p67phox [32]. In line 
with this, we show for the first time that EVs derived from activated 
platelets generate superoxide in a process mediated by Nox-1. Impor-
tantly, Nox-1 inhibition abrogated PDEV-induced platelet activation, 
which could be due to the inhibition of Nox-1 in either platelets and/or 
PDEVs since 0.3 μM ML171 were carried over to platelets. However, 
since higher concentrations of ML171 were required to inhibit platelets 
directly (Supplementary Fig. 3), it is likely that the effects observed were 
due to the inhibition of Nox-1 in PDEVs. Therefore, Nox-1 is proposed as 
a key signalling component of PDEVs that mediate superoxide genera-
tion and the ability of PDEVs to activate nearby platelets. 
In conclusion, Nox-1 modulates PDEV-induced platelet activation. 
Moreover, PDEVs generate superoxide, while Nox-1 inhibition or dele-
tion reduced this response, providing evidence that Nox-1 is key for 
superoxide generation in PDEVs. Future studies will explore which 
mechanisms govern PDEV-platelet interaction, whether Nox-1 regulates 
PDEVs formation induced by different agonists and if PDEVs deliver 
Nox-1 to other cells relevant to thrombo-inflammatory diseases. The 
identification of Nox-1 as a key regulator of PDEV-induced platelet 
activation suggests a novel mechanism through which this redox 
enzyme controls thrombo-inflammatory processes. 
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